10x Genomics, Inc. TXG Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- 10x Genomics, Inc. (TXG) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $10K in Q1 2026.
- How has 10x Genomics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- 10x Genomics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 400.0% year-over-year, from $2K to $10K.
- What is the long-term trend for 10x Genomics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 3 years (2022 to 2025), 10x Genomics, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -100.0% compound annual growth rate (CAGR), from $4.12M to $0.